| 摘要 |
FIELD: medicine, pharmaceutics.SUBSTANCE: invention relates to compound of general structural formulawhich can be used for prevention, treatment, relieving course or prevention of physiological disorders or diseases, associated with hyperplasia or neoplasia. In formula (I) R stands for 5-10-membered mono- or bicyclic heteroaryl, containing 1-3 heteroatoms, selected from O, N and S, which can be optionally substituted with one or more substituents, independently selected from R7, or R stands for 5-10-membered heterocycloalkyl, containing 1-2 heteroatoms, selected from O, N and S, or 5-10-membered heterocycloalkenyl, containing 1-2 heteroatoms, selected from O, N and S, where said 5-10-membered heterocycloalkyl or 5-10-membered heterocycloalkenyl are optionally substituted with one or more substituents, independently selected from R8; or R stands for X; R7 represents halogen; or R7 represents (C-C) alkyl, (C-C) alkenyl, (C) cycloalkyl, 6-membered heterocycloalkyl, containing 1 heteroatom, selected from N, C-aryl, C-aryl (C-C) alkyl, 6-membered heterocycloalkyl (C-C) alkyl, containing 1 heteroatom, selected from O, or (C) cycloalkyl (C-C) alkyl, where said (C-C) alkyl or C-aryl are optionally substituted with one or more substituents, independently selected from R9; or R7 represents -ORa; Ra represents (C-C) alkyl; Rc represents (C-C) alkyl; X represents -NR11R12, Rf represents (C-C) alkyl. Values of radicals R8-R13, Rd are given in the invention formula.EFFECT: invention relates to pharmaceutical composition, containing said compound, and to method of prevention, treatment, relief of course or prophylaxis of physiological disorders or diseases, associated with hyperplasia or neoplasia, responding to stimulation of neutrophil oxidative burst, stimulation of IL-8 release from keratinocytes and to necrosis induction.36 cl, 2 tbl, 753 ex |
